The purpose of this study is to gather information on methocarbamol as a pain management
treatment for ventral or inguinal hernia repair.
Methocarbamol has been part of the pain management treatment for both inpatient and
outpatient procedures at Prisma Health. This study will compare the outcomes of patients who
receive methocarbamol, those who receive the standard opioid pain management treatment, and
those who receive methocarbamol plus the standard opioid pain management treatment.
Participants will be randomized into one of the study groups listed below.
Primary ventral hernia repair or inguinal hernia repair:
Group 1: standard opioid after surgery Group 2: methocarbamol after surgery
Open or robotic ventral hernia repair outpatient:
Group 1: standard opioid after surgery Group 2: standard opioid plus methocarbamol after
surgery
Open or robotic ventral hernia repair inpatient:
Group 1: standard opioid at discharge Group 2: standard opioid plus methocarbamol at
discharge
A total of 120 participants will be included in the study.
Participation will last for about 7 days after surgery.